ABSTRACT
This chapter demonstrates that the use of Bayesian analysis to conduct efficacy assessments of drug combination and monotherapies with censored data. The Bayesian method uses the same likelihood, but adds prior information for the intercept and slope terms as well as the Weibull shape parameter. While frequentist analysis of survival data typically centers on median survival or log-odds of survival, the Bayesian paradigm permits the comparison of survival probabilities without the need for asymptotic approximations. Pre-clinical efficacy assessment is a key component in the decision-making regarding advancing a candidate drug or drug combination into clinical development. Pre-clinical studies are an integral part of drug research and development. The goal of many pre-clinical oncology studies is to discover compounds that produce a tumor-size reducing effect in animals. In-vitro and in-vivo animal studies can play a very important role for assessing the effects of a drug combination.
